How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Mycosis Fungoides Market
- By Disease Stage: Early-stage Mycosis Fungoides, Advanced-stage Mycosis Fungoides, Sézary Syndrome
- By Treatment Modality: Skin-directed therapies, Systemic therapies, Phototherapy, Biologic therapies, Radiation therapy
- By Therapeutic Class: Topical corticosteroids, Retinoids, Histone deacetylase inhibitors (HDACi), Monoclonal antibodies, Chemotherapy agents
- By Patient Demographics: Adult patients, Pediatric patients, Elderly patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Early-stage Mycosis Fungoides leads By Disease Stage at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 268 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 13 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Mycosis Fungoides Market report
A complete, evidence-based study - 11 chapters and 112 sections covering market size, segmentation across 4 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Mallinckrodt Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Spectrum Pharmaceuticals (a subsidiary of Aptevo Therapeutics)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Takeda Pharmaceutical Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sun Pharmaceutical Industries
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bristol-Myers Squibb
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Novartis
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Regeneron Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Kyowa Kirin
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Incyte Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Syndax Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →TG Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Kite Pharma (a Gilead Company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Seattle Genetics (Seagen)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Early-stage Mycosis Fungoides64.5
- Advanced-stage Mycosis Fungoides16.1
- Sézary Syndrome19.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Mallinckrodt Pharmaceuticals13.3
- Spectrum Pharmaceuticals (a subsidiary of Aptevo Therapeutics)18.1
- Takeda Pharmaceutical Company14.9
- Sun Pharmaceutical Industries12.3
- Bristol-Myers Squibb5.0
- Novartis8.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.5
- Europe20.9
- Asia Pacific23.0
- Latin America11.9
- Middle East and Africa10.8
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Mallinckrodt Pharmaceuticals | 74 | 90 | 95 | 95 | 95 | 83 | 89 |
| Spectrum Pharmaceuticals (a subsidiary of Aptevo Therapeutics) | 85 | 93 | 77 | 80 | 86 | 69 | 82 |
| Takeda Pharmaceutical Company | 85 | 69 | 86 | 85 | 73 | 76 | 79 |
| Sun Pharmaceutical Industries | 58 | 67 | 67 | 66 | 59 | 80 | 66 |
| Bristol-Myers Squibb | 76 | 72 | 53 | 63 | 67 | 67 | 66 |
| Novartis | 54 | 71 | 67 | 49 | 52 | 69 | 60 |
| Regeneron Pharmaceuticals | 56 | 64 | 48 | 62 | 62 | 44 | 56 |
| Kyowa Kirin | 57 | 38 | 52 | 56 | 56 | 57 | 53 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Mallinckrodt Pharmaceuticals
- Spectrum Pharmaceuticals (a subsidiary of Aptevo Therapeutics)
- Takeda Pharmaceutical Company
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Mallinckrodt Pharmaceuticals | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Spectrum Pharmaceuticals (a subsidiary of Aptevo Therapeutics) | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Takeda Pharmaceutical Company | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Sun Pharmaceutical Industries | − | ◐ | ✓ | ◐ | − | ◐ |
| Bristol-Myers Squibb | ✓ | ◐ | − | ◐ | ◐ | ◐ |
| Novartis | − | ✓ | ✓ | ◐ | − | − |
| Regeneron Pharmaceuticals | ◐ | ◐ | − | ◐ | ◐ | − |
| Kyowa Kirin | ◐ | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Contender3
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Disease Stage in North America, then scale across Mycosis Fungoides Market — a $560M beachhead inside a $8.86B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Early-stage Mycosis Fungoides
Best fit — highest urgency & budget in Disease Stage.
Advanced-stage Mycosis Fungoides
Strong fit — clear ROI and a fast path to value.
Sézary Syndrome
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Stage in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapeutic Class
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Disease Stage leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Mycosis Fungoides Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Mycosis Fungoides Market is a durable-growth opportunity — $3.37B by 2033, compounding at 8.6%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.6% CAGR
Demand compounds through 2033, outpacing GDP across Disease Stage.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Stage moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Mycosis Fungoides Market — a $3.61B market by 2033. Plan: grow share from 8.8% to 17.5%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 17.5% | Behind |
| Revenue | $289M | $631M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 37.9% | 39.1% | On track |
| Customer retention | 87.6% | 94.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Disease Stage
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Stage share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $66M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Disease Stage leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Sales deck · value proposition
Win the Mycosis Fungoides Market conversation — a $777M market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Stage
Goal Grow share in Disease Stage
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Mycosis Fungoides Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Mycosis Fungoides Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Mycotoxin Feed Testing Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportMycozyme Equivalent Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportMydriatic Eyedrop Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportMyelodysplastic Syndrome Therapeutics Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportMyelofibrosis Therapeutics Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportMyeloproliferative Disorders Clinical Trials Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportMylar Market
Market size, share, segmentation and regional forecast.
$999M market · 2025 base year
View reportMyocardial Infarction Instrument Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportMyocardial Infarction Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportMyocardial Ischemia Drug Market
Market size, share, segmentation and regional forecast.
$526M market · 2025 base year
View reportMyocarditis Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportMyoglobin Kit Market
Market size, share, segmentation and regional forecast.
$496M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy